JP2009519946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009519946A5 JP2009519946A5 JP2008545837A JP2008545837A JP2009519946A5 JP 2009519946 A5 JP2009519946 A5 JP 2009519946A5 JP 2008545837 A JP2008545837 A JP 2008545837A JP 2008545837 A JP2008545837 A JP 2008545837A JP 2009519946 A5 JP2009519946 A5 JP 2009519946A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- heteroaryl
- aryl
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 125000001072 heteroaryl group Chemical group 0.000 claims 52
- 125000000623 heterocyclic group Chemical group 0.000 claims 50
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 44
- 125000000753 cycloalkyl group Chemical group 0.000 claims 39
- 125000003710 aryl alkyl group Chemical group 0.000 claims 33
- 125000003342 alkenyl group Chemical group 0.000 claims 29
- 125000006413 ring segment Chemical group 0.000 claims 28
- 125000000304 alkynyl group Chemical group 0.000 claims 22
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 20
- 229910052757 nitrogen Inorganic materials 0.000 claims 19
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 18
- 229910052717 sulfur Inorganic materials 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000004820 halides Chemical class 0.000 claims 16
- 125000005343 heterocyclic alkyl group Chemical group 0.000 claims 15
- 125000002950 monocyclic group Chemical group 0.000 claims 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 13
- 150000001602 bicycloalkyls Chemical group 0.000 claims 12
- 150000002825 nitriles Chemical class 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000005035 acylthio group Chemical group 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003367 polycyclic group Chemical group 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- -1 heterocyclealkyl Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XCOVZEUBSQCRPL-XLRYRXIZSA-N CC(C)/C=C(\CN(C)C)/NC(c1cc(-c2cccc(CN([C@@H](CN3)C(/N=C\C(C[C@@H]4C(C)(C)[C@H]5C4)C5=C)=O)C3=O)c2OC)cc(N(C)C)c1)=O Chemical compound CC(C)/C=C(\CN(C)C)/NC(c1cc(-c2cccc(CN([C@@H](CN3)C(/N=C\C(C[C@@H]4C(C)(C)[C@H]5C4)C5=C)=O)C3=O)c2OC)cc(N(C)C)c1)=O XCOVZEUBSQCRPL-XLRYRXIZSA-N 0.000 description 1
- AABNAXWGVMACMG-RVTSAGKPSA-N CCN1[C@@H](CNC(c2cc(-c(cccc3CN(C[C@@H]([C@H]4[C@H](C)O)O)[C@@H]4C(NC4[C@@H](C)[C@H](C5)C(C)(C)C5C4)=O)c3OC)cc(N(C)C)c2)=O)CCC1 Chemical compound CCN1[C@@H](CNC(c2cc(-c(cccc3CN(C[C@@H]([C@H]4[C@H](C)O)O)[C@@H]4C(NC4[C@@H](C)[C@H](C5)C(C)(C)C5C4)=O)c3OC)cc(N(C)C)c2)=O)CCC1 AABNAXWGVMACMG-RVTSAGKPSA-N 0.000 description 1
- QADMFZKDSMALTR-DEPFJHGJSA-N CN(C)c1cc(C(N[C@]2(C3)C3c3ccccc3N(C)C2)=O)cc(-c2cccc(CN(CSC3)[C@@H]3C(N)=O)c2OC)c1 Chemical compound CN(C)c1cc(C(N[C@]2(C3)C3c3ccccc3N(C)C2)=O)cc(-c2cccc(CN(CSC3)[C@@H]3C(N)=O)c2OC)c1 QADMFZKDSMALTR-DEPFJHGJSA-N 0.000 description 1
- IIVZSHWVSFPZSI-TUJBTNQDSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H](C1)N(Cc(cccc2-c3cc(N(C)C)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)C[C@H]1N)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H](C1)N(Cc(cccc2-c3cc(N(C)C)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)C[C@H]1N)=O IIVZSHWVSFPZSI-TUJBTNQDSA-N 0.000 description 1
- WNABZQBRQYVTSM-ZGBQKGHYSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc(N(C)C)cc(C(NC4(C5)C5c5ccccc5N(C)C4)=O)c3)c2OC)CCC1)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc(N(C)C)cc(C(NC4(C5)C5c5ccccc5N(C)C4)=O)c3)c2OC)CCC1)=O WNABZQBRQYVTSM-ZGBQKGHYSA-N 0.000 description 1
- ZAUOEWHAZNHKQB-ZVOHYFGASA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc(N(C)C)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)CCCC1)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc(N(C)C)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)CCCC1)=O ZAUOEWHAZNHKQB-ZVOHYFGASA-N 0.000 description 1
- CMNSJCMBQNWBKW-RUWGMCBSSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc(N(C)C)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)CCOC1)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc(N(C)C)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)CCOC1)=O CMNSJCMBQNWBKW-RUWGMCBSSA-N 0.000 description 1
- OAGDODCPOMRXOF-GDWNLENFSA-N C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc(N(C)C)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)CSC1(C)C)=O Chemical compound C[C@@H]([C@H](C1)C(C)(C)[C@H]1C1)[C@H]1NC([C@H]1N(Cc(cccc2-c3cc(N(C)C)cc(C(N[C@@H]4CN(C)c5ccccc5C4)=O)c3)c2OC)CSC1(C)C)=O OAGDODCPOMRXOF-GDWNLENFSA-N 0.000 description 1
- KZSUXWLVBLEXDO-DIAGZHNISA-N C[C@@H]([C@H]1[C@@H](C(NC(CC2C(C)(C)[C@H]3C2)C3=C)=O)N(Cc2cccc(-c(cc3)ccc3C(N(C)C)=O)c2)C[C@@H]1O)O Chemical compound C[C@@H]([C@H]1[C@@H](C(NC(CC2C(C)(C)[C@H]3C2)C3=C)=O)N(Cc2cccc(-c(cc3)ccc3C(N(C)C)=O)c2)C[C@@H]1O)O KZSUXWLVBLEXDO-DIAGZHNISA-N 0.000 description 1
- WWZWYTCPVUBWFH-INRSGBKRSA-N C[C@@H]([C@H]1[C@@H](C(NC2C(C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(-c3cc(C(N[C@@H](Cc4ccccc4)CN(C)C)=O)cc(N(C)C)c3)c2OC)CC1)O Chemical compound C[C@@H]([C@H]1[C@@H](C(NC2C(C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(-c3cc(C(N[C@@H](Cc4ccccc4)CN(C)C)=O)cc(N(C)C)c3)c2OC)CC1)O WWZWYTCPVUBWFH-INRSGBKRSA-N 0.000 description 1
- XOKSLPVRUOBDEW-VGMNWLOBSA-N C[C@H]1[C@H](C2)C(C)(C)[C@H]2CC1 Chemical compound C[C@H]1[C@H](C2)C(C)(C)[C@H]2CC1 XOKSLPVRUOBDEW-VGMNWLOBSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75098705P | 2005-12-16 | 2005-12-16 | |
| US60/750,987 | 2005-12-16 | ||
| PCT/US2006/047861 WO2007075387A1 (en) | 2005-12-16 | 2006-12-15 | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009519946A JP2009519946A (ja) | 2009-05-21 |
| JP2009519946A5 true JP2009519946A5 (enExample) | 2010-01-28 |
| JP5341521B2 JP5341521B2 (ja) | 2013-11-13 |
Family
ID=38024107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008545837A Expired - Fee Related JP5341521B2 (ja) | 2005-12-16 | 2006-12-15 | タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US7745464B2 (enExample) |
| EP (1) | EP1973875B1 (enExample) |
| JP (1) | JP5341521B2 (enExample) |
| KR (1) | KR101373911B1 (enExample) |
| CN (1) | CN101374807B (enExample) |
| AR (1) | AR058855A1 (enExample) |
| AU (1) | AU2006329879B2 (enExample) |
| BR (1) | BRPI0619968A2 (enExample) |
| CA (1) | CA2633958C (enExample) |
| EC (1) | ECSP088607A (enExample) |
| ES (1) | ES2494765T3 (enExample) |
| IL (1) | IL192023A (enExample) |
| JO (1) | JO2918B1 (enExample) |
| MA (1) | MA30144B1 (enExample) |
| MX (1) | MX2008007687A (enExample) |
| MY (1) | MY153232A (enExample) |
| NO (1) | NO20083050L (enExample) |
| NZ (1) | NZ569660A (enExample) |
| PE (1) | PE20071033A1 (enExample) |
| RU (1) | RU2424230C2 (enExample) |
| SA (1) | SA06270462B1 (enExample) |
| SG (1) | SG170727A1 (enExample) |
| TN (1) | TNSN08258A1 (enExample) |
| TW (1) | TWI403320B (enExample) |
| WO (1) | WO2007075387A1 (enExample) |
| ZA (1) | ZA200805822B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| CN102015606B (zh) | 2007-06-08 | 2015-02-04 | 满康德股份有限公司 | IRE-1α抑制剂 |
| CN101906056B (zh) * | 2009-06-04 | 2013-10-30 | 中国科学院广州生物医药与健康研究院 | 作为m2抑制剂的环烷胺类化合物及其应用 |
| US8314250B2 (en) | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| FR3048698B1 (fr) * | 2016-03-11 | 2021-03-05 | Univ Claude Bernard Lyon | Inhibiteurs de l'interaction bcl2 l10 / recepteur ip3 |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| PH12022550597A1 (en) | 2019-09-16 | 2024-03-04 | Takeda Pharmaceuticals Co | Azole-fused pyridazin-3(2h)-one derivatives |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0382213B1 (en) | 1989-02-08 | 1995-05-10 | Otsuka Pharmaceutical Co., Ltd. | Biphenyl derivative, nerve cell degeneration repairing or protecting agent and process for preparing a phenyl derivative contained in the agent |
| DK0730590T3 (da) | 1993-11-24 | 2001-03-19 | Du Pont Pharm Co | Isoxazolin og isozazol fibrinogenreceptorantagonister |
| US6693123B2 (en) * | 1995-11-06 | 2004-02-17 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| KR100399361B1 (ko) | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| EP1125925A1 (en) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| PT1268418E (pt) * | 2000-03-27 | 2006-08-31 | Applied Research Systems | Derivados da pirrolidina farmacologicamente activos com inibidores bax |
| AU2001284942A1 (en) | 2000-08-16 | 2002-02-25 | Georgetown University Medical Center | Small molecule inhibitors targeted at bcl-2 |
| US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US20040147473A1 (en) | 2000-11-10 | 2004-07-29 | Warrell Raymond P. | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| US7855183B2 (en) | 2000-11-10 | 2010-12-21 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
| ES2349349T3 (es) | 2001-05-30 | 2010-12-30 | The Regents Of The University Of Michigan | Asociacion sinergica de (-)-gosipol con docetaxel o paclitaxel para el tratamiento de cancer. |
| US20030119894A1 (en) | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
| AU2003223708A1 (en) * | 2002-04-23 | 2003-11-10 | Axys Pharmaceuticals, Inc. | Novel phenyl derivatives as inducers of apoptosis |
| US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| NZ539162A (en) * | 2002-09-04 | 2006-07-28 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| EP1581213A4 (en) * | 2002-12-18 | 2008-11-19 | Cytovia Inc | 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE |
| WO2004099158A1 (en) * | 2003-04-30 | 2004-11-18 | Ricerca Biosciences, Llc. | Monocyclic diazodioxide based bcl-2 protein antagonists |
| CA2526387A1 (en) * | 2003-06-12 | 2004-12-23 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
| AU2004272345A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| DE602004025504D1 (de) * | 2003-12-23 | 2010-03-25 | Novartis Ag | Bicyclische heterocyclische p-38-kinase-inhibitoren |
| TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| PL1768966T3 (pl) | 2004-06-17 | 2012-08-31 | Infinity Discovery Inc | Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi |
| CN101014635A (zh) | 2004-08-30 | 2007-08-08 | 三菱丽阳株式会社 | 光学用共聚物及由其构成的成形体 |
| TW200626142A (en) * | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| TW200803740A (en) | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
-
2006
- 2006-11-30 TW TW095144471A patent/TWI403320B/zh not_active IP Right Cessation
- 2006-12-14 PE PE2006001602A patent/PE20071033A1/es not_active Application Discontinuation
- 2006-12-15 EP EP06845504.7A patent/EP1973875B1/en active Active
- 2006-12-15 SG SG201101864-5A patent/SG170727A1/en unknown
- 2006-12-15 KR KR1020087017168A patent/KR101373911B1/ko not_active Expired - Fee Related
- 2006-12-15 MY MYPI20082026A patent/MY153232A/en unknown
- 2006-12-15 CN CN2006800528798A patent/CN101374807B/zh not_active Expired - Fee Related
- 2006-12-15 AR ARP060105561A patent/AR058855A1/es unknown
- 2006-12-15 BR BRPI0619968-2A patent/BRPI0619968A2/pt not_active IP Right Cessation
- 2006-12-15 NZ NZ569660A patent/NZ569660A/en not_active IP Right Cessation
- 2006-12-15 WO PCT/US2006/047861 patent/WO2007075387A1/en not_active Ceased
- 2006-12-15 RU RU2008128569/04A patent/RU2424230C2/ru not_active IP Right Cessation
- 2006-12-15 US US11/640,480 patent/US7745464B2/en not_active Expired - Fee Related
- 2006-12-15 AU AU2006329879A patent/AU2006329879B2/en not_active Ceased
- 2006-12-15 MX MX2008007687A patent/MX2008007687A/es active IP Right Grant
- 2006-12-15 ES ES06845504.7T patent/ES2494765T3/es active Active
- 2006-12-15 JP JP2008545837A patent/JP5341521B2/ja not_active Expired - Fee Related
- 2006-12-15 CA CA2633958A patent/CA2633958C/en not_active Expired - Fee Related
- 2006-12-16 SA SA6270462A patent/SA06270462B1/ar unknown
- 2006-12-17 JO JO2006461A patent/JO2918B1/en active
-
2008
- 2008-06-10 IL IL192023A patent/IL192023A/en not_active IP Right Cessation
- 2008-06-13 TN TNP2008000258A patent/TNSN08258A1/en unknown
- 2008-07-03 ZA ZA200805822A patent/ZA200805822B/xx unknown
- 2008-07-04 MA MA31089A patent/MA30144B1/fr unknown
- 2008-07-07 NO NO20083050A patent/NO20083050L/no not_active Application Discontinuation
- 2008-07-07 EC EC2008008607A patent/ECSP088607A/es unknown
-
2010
- 2010-04-02 US US12/753,319 patent/US8304428B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010077141A5 (enExample) | ||
| JP2009519946A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| JP2006515587A5 (enExample) | ||
| JP2010501562A5 (enExample) | ||
| JP2015509983A5 (enExample) | ||
| RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP2005519916A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| CA2632626A1 (en) | Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection | |
| JP2006507220A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2013508373A5 (enExample) | ||
| JP2013504593A5 (enExample) | ||
| JP2013510883A5 (enExample) | ||
| JP2002524463A5 (enExample) | ||
| JP2012506872A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| JP2014530881A5 (enExample) | ||
| JPWO2020123827A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JPWO2023099592A5 (enExample) | ||
| JP2017508816A5 (enExample) | ||
| JP2008531558A5 (enExample) |